ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Tau Conformation-Selective HSP70 Inhibition
Inhibitors containing molecular recognition elements that only bind HSP70 when it adopts conformations specific to pathological tau engagement, exploiting differences in HSP70 structure when bound to misfolded versus properly folded tau .
drug discovery
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Inhibitors containing molecular recognition elements that only bind HSP70 when it adopts conformations specific to pathological tau engagement, exploiting differences in HSP70 structure when bound to misfolded versus properly folded tau species.
🧬 Mechanism
🔗 Mechanism from KG for HSPA1A
Auto-built from this analysis's top knowledge-graph edges.
graph TD
HSPA1A["HSPA1A"] -->|protein interactio| STUB1["STUB1"]
MAPT["MAPT"] -->|regulates| HSPA1A_1["HSPA1A"]
Bifunctional_PROTACs["Bifunctional PROTACs"] -->|targets| HSPA1A_2["HSPA1A"]
HSPA1A_3["HSPA1A"] -->|regulates| tau_protein["tau protein"]
HSPA1A_4["HSPA1A"] -->|regulates| proteasomal_degradation_p["proteasomal degradation pathway"]
style HSPA1A fill:#ce93d8,stroke:#333,color:#000
style STUB1 fill:#ce93d8,stroke:#333,color:#000
style MAPT fill:#ce93d8,stroke:#333,color:#000
style HSPA1A_1 fill:#ce93d8,stroke:#333,color:#000
style Bifunctional_PROTACs fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_2 fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_3 fill:#4fc3f7,stroke:#333,color:#000
style tau_protein fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_4 fill:#4fc3f7,stroke:#333,color:#000
style proteasomal_degradation_p fill:#81c784,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
Supports
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system.
Supports
Mechanism of Tau protein incorporation into exosomes via cooperative recognition of KFERQ-like motifs by LAMP2A and HSP70.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HSPA1A
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HSPA1A.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0511
Events (7d)
0
Price History
▲5.2%💾 Resource Usage
LLM Tokens
18,738
$0.1124
Total Cost
$0.1124
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we compare the binding affinity (Kd) of the conformation-selective inhibitor for HSP70 immunoprecipitated from tau-filament-enriched AD brain homogenates vs. age-matched healthy hippocampus, THEN w | ≥5-fold selectivity for disease-state HSP70 (Kd ratio disease/normal ≥5) | — no observation — | pending | 0.00 |
| IF we administer a conformation-selective HSP70 inhibitor (vs. vehicle) to rTg4510 tauopathy mice for 8 weeks at 10mg/kg/day, THEN we will observe at least a 30% reduction in Sarkisovan-insoluble tau | ≥30% decrease in Sarkisovan-insoluble tau in hippocampus; increased soluble tau ratio; reduced tau seeding in bioassay | — no observation — | pending | 0.00 |
🔮 Falsifiable Predictions (2)
pendingconf 0%
IF we administer a conformation-selective HSP70 inhibitor (vs. vehicle) to rTg4510 tauopathy mice for 8 weeks at 10mg/kg/day, THEN we will observe at least a 30% reduction in Sarkisovan-insoluble tau fraction in the hippocampus compared to vehicle controls.
Predicted outcome: ≥30% decrease in Sarkisovan-insoluble tau in hippocampus; increased soluble tau ratio; reduced tau seeding in bioassay
Falsification: No significant difference (p>0.05) in Sarkisovan-insoluble tau between treatment and vehicle groups
pendingconf 0%
IF we compare the binding affinity (Kd) of the conformation-selective inhibitor for HSP70 immunoprecipitated from tau-filament-enriched AD brain homogenates vs. age-matched healthy hippocampus, THEN we will measure at least a 5-fold higher affinity (lower Kd) for the disease-state HSP70 conformation
Predicted outcome: ≥5-fold selectivity for disease-state HSP70 (Kd ratio disease/normal ≥5)
Falsification: Binding affinities do not differ by ≥5-fold between disease and normal HSP70 preparations
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.